• 한국의료질향상학회지
• /
• 제27권2호
• /
• pp.73-82
• /
• 2021

Purpose: This study aims to examine the quality of tuberculosis (TB) care after the 1st to 3rd national quality assessment (QA) program for TB healthcare service in Korea was conducted. Methods: We analyzed Health Insurance Review & Assessment Service (HIRA) claims data of new TB patients during the period of January to June from 2018-2020. The new TB patients were defined as TB patients reported to Korea Centers for Disease Control and Prevention Agency (KCDA). The unit of analysis was the patient. Chi-square tests were used to analyze the differences in indicator value according to the types of medical facilities. The QA indicators of TB care were divided into 3 areas consisting of the following 7 quality indicators: 4 indicators of diagnosis test (the rate of acid-fast bacilli smear, the rate of acid-fast bacilli culture, the rate of Mycobacterium tuberculosis-polymerase chain reaction, drug susceptibility test), 1 compliance of treatment guideline, and 2 indicators of care management of TB patients (encounter rate, day of therapy). Results: The QA program for TB care was conducted among 8,246 patients from 534 facilities in 2020. The value of the 7 quality indicators was shown to increase as a result of the QA program. The indicators of the diagnostic test were all higher than 95%, with the exception of the drug susceptibility test which was 84.8%. Both indicators for care management of TB patients were 88.5%. Conclusion: The quality of TB care has been improving with the implementation of the QA program. In order to continue to improve the quality of TB care, it will be necessary to disclose the results of the QA program in medical facilities in the future.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권5호
• /
• pp.3363-3368
• /
• 2013

Background: The burden due to cancers is an emerging public health concern especially in resource-limited countries like Nigeria. The WHO estimates that cancer kills more people than tuberculosis, HIV/AIDS and malaria combined. As people in Nigeria and other developing countries are beginning to survive infectious diseases, there is an observed epidemiologic transition to chronic diseases, such as cancers. In 2008, 75 out of 1,000 Nigerians died of cancer. Despite the rising incidence and public health importance, Nigeria lacks an organized and comprehensive strategy to deal with cancers. Materials and Methods: This article reviewed 30 peer-reviewed manuscripts on cancer care in four countries. It highlights the limitations to cancer care in Nigeria; due to lack of awareness, low health literacy, absence of organized screening programs, inadequate manpower (in terms of quality and quantity) as well as limited treatment options. Results: This review led to the formulation of a proposal for Nigerian National Cancer Policy, mainly drawn from effective strategies used in Canada, Brazil and Kenya. This is a vertical cancer program that is patient-centered with an emphasis on tobacco control and cancer disease screening (similar to Canada and Brazil). Additionally, it emphasizes primary cancer prevention (similar to Kenya). Its horizontal integration with other disease programs like HIV/AIDS will improve affordability in a poor resourced country like Nigeria. Capacity building for health professionals, hub-and-spoke implementation of screening services, as well as investment in effective treatment options and increased research in cancer care are essential. International 'twinning collaborations' between institutions in richer countries and Nigeria will enhance effective knowledge translation and improve the quality of patient care. Conclusions: A national cancer policy must be developed and implemented in Nigeria in order to overcome the present limitations which help contribute to the observed increases in cancer morbidity and mortality rates. Cancer control is feasible in Nigeria if the nation was to consider and employ some of the cost-effective strategies proposed here.

• Annals of Clinical Microbiology
• /
• 제18권2호
• /
• pp.37-43
• /
• 2015

배경: 결핵은 전세계적으로 단일 원인균으로는 가장 높은 치사율을 가진 질병이다. 결핵의 치료에 있어서 마이코박테리아를 빠르고 정확하게 확인하는 것이 필수적이다. 본 연구에서는 임상 객담 검체의 도말 슬라이드에서 결핵균과 비결핵 항산균의 감별을 위해 Peptide Nucleic Acid (PNA) Probe를 이용한 FISH assay를 평가하고자 한다. 방법: 결핵균과 비결핵 항산균의 16s rRNA를 타겟으로 한 PNA probe를 합성하였다. 각 probe의 특이도는 표준 균주인 Mycobacterium tuberculosis ATCC 13950, M. kansasii ATCC 12479, 임상 검체에서 분리된 마이코박테리아 3종(M. abscessus, M. avium, and M. intracellulare) 그리고 호흡기계에서 흔히 분리되는 10종류의 박테리아를 이용하였다. Centers for Disease Control and Prevention (CDC)의 Acid fast bacili (AFB) 염색 기준상 trace 이상인 128개의 임상 객담 검체를 이용하여 Probe의 성능을 평가하였다. PNA FISH와 항산균 염색결과는 CDC 기준에 따라 단계를 분류하고 서로 비교하였다. 결과: 결핵균과 비결핵 항산균 특이 PNA probe는 결핵균과 M. kansasii 표준 균주 그리고 임상검체에서 분리된 3종의 마이코박테리아에 대해 특이적인 반응을 보였고 다른 박테리아와 교차반응을 보이지 않았다. 또한 89개의 결핵균 배양 양성 객담 검체와 29개의 비결핵 항산균 배양 양성 객담 검체에 각각 특이적인 반응을 보였고 CDC 기준에 따라 분류한 PNA FISH와 AFB염색 결과는 2+ 이상의 검체에서 서로 잘 일치하였다. 결론: PNA FISH 방법은 임상 객담 검체에서 결핵을 진단하고, 항산균과 비결핵 항산균을 구분하는데 있어서 민감하고 정확한 결과를 보였다.

• Journal of Chest Surgery
• /
• 제24권11호
• /
• pp.1098-1106
• /
• 1991

Atelectasis may be defined as collapse of the lung due to absence of air within the alveoli. It may involve anatomic segments, lobes, or whole lungs but also may be a diffuse miliary process, as in the adult respiratory distress syndrome. The key to treatment are the anticipation and prevention of atelectasis in various clinical situations, the recognition and treatment of underlying disease, and the prompt initiation of vigorous treatment once atelectasis is found. Repeated assessment by physical examination is necessary to determine the presence of atelectasis and its response to treatment. During the period of January, 1981 to October, 1990, 100 patients with atelectasis were treated in the department of Thoracic and Cardiovascular Surgery, Pusan National University Hospital. There were 70 males and 30 females ranging from 3 days to 79 years of age. The occurrence ratio of right to left side was 2.1 : 1. The underlying pathologic lesions of atelectasis were pneumonia with effusion(28), lung ca.(24), pulmonary tuberculosis(24), and chronic empyema(9), The treatment procedure for atelectasis were closed thoracostomy in 26 cases, ressection in 21 cases, therapeutic bronchoscopy in 14 cases and etc.

• Tuberculosis and Respiratory Diseases
• /
• 제65권3호
• /
• pp.225-229
• /
• 2008

저자들은 폐색전증과 심부정맥 혈전증을 이전에 진단받았던 말기 전립선암환자에서 외상성 뇌출혈로 인해 항응고제 치료를 시행하지 못하여 하대정맥 필터를 삽입 후 하지 부종, 하지 맥압 소실, 급성 신부전 및 DIC 등으로 사망한 phlegmasia cerulea dolens 1예를 경험하였기에 문헌고찰과 함께 보고하는 바이다.

• Tuberculosis and Respiratory Diseases
• /
• 제84권1호
• /
• pp.35-45
• /
• 2021

Globally, cardiovascular diseases and chronic obstructive pulmonary disease (COPD) are the leading causes of the non-communicable disease burden. Overlapping symptoms such as breathing difficulty and fatigue, with a lack of awareness about COPD among physicians, are key reasons for under-diagnosis and resulting sub-optimal care relative to COPD. Much has been published in the past on the pathogenesis and implications of cardiovascular comorbidities in COPD. However, a comprehensive review of the prevalence and impact of COPD management in commonly encountered cardiac diseases is lacking. The purpose of this study was to summarize the current knowledge regarding the prevalence of COPD in heart failure, ischemic heart disease, and atrial fibrillation. We also discuss the real-life clinical presentation and practical implications of managing COPD in cardiac diseases. We searched PubMed, Scopus, EMBASE, and Google Scholar for studies published 1981-May 2020 reporting the prevalence of COPD in the three specified cardiac diseases. COPD has high prevalence in heart failure, atrial fibrillation, and ischemic heart disease. Despite this, COPD remains under-diagnosed and under-managed in the majority of patients with cardiac diseases. The clinical implications of the diagnosis of COPD in cardiac disease includes the recognition of hyperinflation (a treatable trait), implementation of acute exacerbations of COPD (AECOPD) prevention strategies, and reducing the risk of overuse of diuretics. The pharmacological agents for the management of COPD have shown a beneficial effect on cardiac functions and mortality. The appropriate management of COPD improves the cardiovascular outcomes by reducing hyperinflation and preventing AECOPD, thus reducing the risk of mortality, improving exercise tolerance, and quality of life.

• Tuberculosis and Respiratory Diseases
• /
• 제82권2호
• /
• pp.126-132
• /
• 2019

Background: The development of lung cancer results from the interaction between genetic mutations and dynamic epigenetic alterations, although the exact mechanisms are not completely understood. Changes in DNA methylation may be a promising biomarker for early detection and prognosis of lung cancer. We evaluated the serial changes in genome-wide DNA methylation patterns in blood samples of lung cancer patients. Methods: Blood samples were obtained for three consecutive years from three patients (2 years before, 1 year before, and after lung cancer detection) and from three control subjects (without lung cancer). We used the MethylationEPIC BeadChip method, which covers the 850,000 bp cytosine-phosphate-guanine (CpG) site, to conduct an epigenome-wide analysis. Significant differentially methylated regions (DMRs) were identified using p-values <0.05 in a correlation test identifying serial methylation changes and serial increase or decrease in ${\beta}$ value above 0.1 for three consecutive years. Results: We found three significant CpG sites with differentially methylated ${\beta}$ values and 7,105 CpG sites with significant correlation from control patients without lung cancer. However, there were no significant DMRs. In contrast, we found 11 significant CpG sites with differentially methylated ${\beta}$ values and 10,562 CpG sites with significant correlation from patients with lung cancer. There were two significant DMRs: cg21126229 (RNF212) and cg27098574 (BCAR1). Conclusion: This study revealed DNA methylation changes that might be implicated in lung cancer development. The DNA methylation changes may be the possible candidate target regions for the early detection and prevention of lung cancer.

• Pediatric Infection and Vaccine
• /
• 제21권3호
• /
• pp.191-198
• /
• 2014

목적: 본 연구는 2개 대학 병원에서 폐결핵으로 진단 받고 치료 받았던 학동기 소아와 청소년들을 대상으로 임상 양상과 접촉 병력을 파악하고 접촉자 검진 실태에 대하여 알아보고자 하였다. 방법: 2008년부터 2012년까지 부산대학교어린이병원과 부산대학병원에서 활동 폐결핵으로 진단 받고 치료 받은 10-18세, 54명의 환자를 대상으로 하였다. 환자들의 의무기록을 통하여 진단 당시 임상 양상, 추정 감염 경로, 감염원과의 관계와 미생물학적 검사, 영상학적 검사, 접촉자 검진의 여부, 잠복결핵감염 치료 여부, 노출 후 결핵 발병까지의 기간 등을 후향적으로 조사하였다. 결과: 연령 중앙값은 16세였으며, 10-14세가 11명(20.4%), 15-18세가 43명(79.6%)이었다. 54명 중 35명(64.8%)은 전염성 결핵 환자와 접촉력이 없었고, 19명(35.2%)에서 접촉력이 있었다. 19명 중 가족 접촉자 군은 10명(52.6%)였고, 비가족 접촉자 군은 9명(47.4%)으로 학교 급우였다. 결핵 노출 후 접촉자 검진을 받은 환자는 가족 접촉자 군에서 10명 중 1명 이었고, 비가족 접촉자 군에서 9명 중 6명 이었다. 접촉자 검진을 받은 7명 중 3명이 활동 폐결핵, 1명이 잠복결핵감염, 3명은 결핵 감염의 소견은 없었다. 활동 결핵 환자와 노출 후 폐결핵으로 진단되기까지의 기간은 가족 접촉자 군에서 중간값이 2년, 비가족 접촉자 군에서 중간값 0.23년이었다. 결론: 학교 내 접촉자 검진과 같이 접촉자 검진이 적절하게 시행된다면 청소년 결핵을 조기에 발견하고 치료할 수 있게 되며, 이는 결핵의 확산 방지에 도움이 될 것이다.

• Tuberculosis and Respiratory Diseases
• /
• 제67권4호
• /
• pp.281-302
• /
• 2009

The successful treatment of community-acquired pneumonia requires appropriate, empirical antimicrobial therapy. The etiology and antimicrobial susceptibility of major pneumonia pathogens can differ by country. Therefore, the ideal treatment guidelines for community-acquired pneumonia should be based on the studies performed in each country. We developed a treatment guideline for community-acquired pneumonia for immunocompetent adults in Korea. This guideline was developed by the joint committee of the Korean Society for Chemotherapy, the Korean Society of Infectious Diseases, and the Korean Academy of Tuberculosis and Respiratory diseases.

• Tuberculosis and Respiratory Diseases
• /
• 제79권3호
• /
• pp.111-120
• /
• 2016

Asthma is a prevalent and serious health problem in Korea. Recently, the Korean Asthma Guideline has been updated by The Korean Academy of Tuberculosis and Respiratory Diseases (KATRD) in an effort to improve the clinical management of asthma. This guideline focuses on adult patients with asthma and aims to deliver up to date scientific evidence and recommendations to general physicians for the management of asthma. For this purpose, this guideline was updated following systematic review and meta-analysis of recent studies and adapting some points of international guidelines (Global Initiative for Asthma [GINA] report 2014, National Asthma Education and Prevention Program [NAEPP] 2007, British Thoracic Society [BTS/SIGN] asthma guideline 2012, and Canadian asthma guideline 2012). Updated issues include recommendations derived using the population, intervention, comparison, and outcomes (PICO) model, which produced 20 clinical questions on the management of asthma. It also covers a new definition of asthma, the importance of confirming various airflow limitations with spirometry, the epidemiology and the diagnostic flow of asthma in Korea, the importance and evidence for inhaled corticosteroids (ICS) and ICS/formoterol as a single maintenance and acute therapy in the stepwise management of asthma, assessment of severity of asthma and management of exacerbation, and an action plan to cope with exacerbation. This guideline includes clinical assessments, and treatment of asthma-chronic obstructive pulmonary disease overlap syndrome, management of asthma in specific conditions including severe asthma, elderly asthma, cough variant asthma, exercise-induced bronchial contraction, etc. The revised Korean Asthma Guideline is expected to be a useful resource in the management of asthma.